The cost of prescription drugs in the U.S. has long outpaced that of peer nations, a dynamic driven by a combination of regulatory gaps, market forces, and lobbying pressure. Now, President Donald Trump is once again trying to tackle the issue—this time through an Executive Order that aims to pressure pharmaceutical companies to voluntarily lower … Read more
This systematic review and meta-analysis examines data for patients with diabetes and/or obesity from trials of GLP1-RA treatment to evaluate psychiatric, cognitive, and quality-of-life outcomes compared with placebo.
Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025 Mar;49(3):452-463. doi: 10.1038/s41366-024-01599-z. Epub 2024 Aug 10. PMID: 39127792; PMCID: PMC11931505. Published 10 August 2024 This review article explores the potential of precision medicine to improve obesity management, moving away from the current trial-and-error approach for selecting medications. … Read more
Weight-loss medications and bariatric surgery have both been found effective at helping people shed excess pounds — and now a new study explores their link to obesity-related cancer (ORC) risk. Obesity is a known risk factor for certain types of cancers, and has also been shown to impact cancer survival. Obesity-related cancers include multiple myeloma, … Read more
On the heels of President Donald Trump’s Monday announcement of an executive order that will slash prescription drug prices in the U.S., the spotlight is on current costs and how much Americans could save. The president’s order calls for “most favored nations drug pricing” — which means “the lowest price paid for a drug in … Read more
Nature Communications, Published online: 13 May 2025; doi:10.1038/s41467-025-59485-9 Myostatin and activin A are the two primary negative regulators of muscle mass. Blocking these circulating ligands during GLP-1 therapy induces improved body composition through preservation of lean mass and enhanced fat mass loss in obese primates.
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top. Continue Reading Category: Obesity, Illnesses and conditions, Body & Mind Tags: GLP-1 receptor agonists, Obesity, Weight Loss, clinical trials, Weill Cornell Medicine
This academic paper examines whether tailoring anti-obesity medication based on specific patient characteristics, or “phenotypes,” improves weight loss outcomes compared to standard treatment. Researchers classified individuals with obesity into four main phenotypes: “hungry brain” (abnormal satiation), “emotional hunger” (hedonic eating), “hungry gut” (abnormal satiety), and “slow burn” (decreased metabolic rate). A clinical trial showed that the phenotype-guided approach resulted in significantly greater weight loss and … Read more
Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and researchers have struggled to answer a deceptively simple question: Who should be taking them? The medications are highly effective at inducing weight loss, and most Americans are overweight or have obesity. But GLP-1s are also expensive, … Read more
Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at year’s European Congress on Obesity (ECO 2025) suggests.